RNS Number : 0337F
ValiRx PLC
04 March 2020

ValiRx Plc

("ValiRx" or the "Company")

Shareholder Requisition Notice

London, UK, 4 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has received a letter from a group of shareholders (the "Letter") who hold in excess of 5% of the issued share capital of the Company, requiring that the Company convene, as soon as reasonably practicable, a general meeting, at which resolutions will be proposed to remove George Morris and Satu Vainikka as directors of the Company.

The Letter is a requisition under section 303 of the Companies Act 2006.

The Company is mindful that, pursuant to section 304 of the Companies Act 2006, the Company must post a notice convening a general meeting within 21 days from the date on which the requisition notice was received, and this general meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

For more information, please contact:

ValiRx plc	**Tel: +44 (0) 20 3008 4416**
	www.valirx.com
Kevin Alexander, Non-executive Director	**Tel: +44 (0) 20 3008 4416**
Tarquin Edwards, Head of Communications.	**Tel: +44 (0) 7879 458 364**
	tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)	**Tel: +44 (0) 20 7213 0880**
Liam Murray / Jo Turner / Ludovico Lazzaretti	
Allenby Capital Limited (Joint Broker)	**Tel: +44 (0) 20 3328 5656**
Jeremy Porter / Alex Brearley (Corporate Finance)	
Kelly Gardiner (Equity Sales)	

ETX Capital Limited (Joint Broker) **Tel: +44 (0) 20 7392 1568**
Thomas Smith

Novum Securities Limited (Joint Broker) **Tel: +44 (0) 20 7399 9400**
Colin Rowbury

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCJIMATMTTMBFM